J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets

[cafead]

via After expanding its antibody-drug conjugate (ADC) deal with Synaffix last November to the tune of $1 billion, Mersana Therapeutics is back with another major deal. This time, Johnson & Johnson's Janssen unit is doling out $40 million upfront and more than $1 billion in biobucks for ADCs spanning three targets.

article source